Unlock stock picks and a broker-level newsfeed that powers Wall Street.
NasdaqCM - Delayed Quote USD

IRIDEX Corporation (IRIX)

Compare
0.9991
+0.1128
+(12.73%)
At close: March 28 at 4:00:01 PM EDT
0.9521
-0.05
(-4.70%)
After hours: March 28 at 7:48:29 PM EDT
Loading Chart for IRIX
  • Previous Close 0.8863
  • Open 1.0600
  • Bid --
  • Ask --
  • Day's Range 0.9101 - 1.0652
  • 52 Week Range 0.7800 - 3.6500
  • Volume 450,008
  • Avg. Volume 68,869
  • Market Cap (intraday) 16.621M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.6700
  • Earnings Date May 12, 2025 - May 16, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

www.iridex.com

--

Full Time Employees

December 28

Fiscal Year Ends

Recent News: IRIX

View More

Performance Overview: IRIX

Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

IRIX
40.53%
S&P 500 (^GSPC)
5.11%

1-Year Return

IRIX
66.47%
S&P 500 (^GSPC)
6.22%

3-Year Return

IRIX
79.27%
S&P 500 (^GSPC)
21.97%

5-Year Return

IRIX
43.87%
S&P 500 (^GSPC)
119.59%

Compare To: IRIX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: IRIX

View More

Valuation Measures

Annual
As of 3/28/2025
  • Market Cap

    16.62M

  • Enterprise Value

    17.67M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.34

  • Price/Book (mrq)

    6.34

  • Enterprise Value/Revenue

    0.36

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -18.31%

  • Return on Assets (ttm)

    -16.32%

  • Return on Equity (ttm)

    -153.37%

  • Revenue (ttm)

    48.67M

  • Net Income Avi to Common (ttm)

    -8.91M

  • Diluted EPS (ttm)

    -0.6700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.39M

  • Total Debt/Equity (mrq)

    221.41%

  • Levered Free Cash Flow (ttm)

    -2.46M

Research Analysis: IRIX

View More

Company Insights: IRIX

Research Reports: IRIX

View More

People Also Watch